Back to Browse Journals » Clinical Pharmacology: Advances and Applications » Volume 3

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome

Authors Ohanian M, Cable CC, Halka KK

Published Date May 2011 Volume 2011:3 Pages 5—12

DOI http://dx.doi.org/10.2147/CPAA.S17904

Published 24 May 2011

Maro Ohanian, Christian Cable, Kathleen Halka
Department of Hematology and Oncology, Scott and White Healthcare, The Texas A&M Health Science Center College of Medicine, Temple, TX, USA

Abstract: This case report describes how eculizumab reversed neurologic impairment and improved renal damage in severe atypical hemolytic uremic syndrome. A 50-year-old female, after presenting with diarrhea and abdominal pain, developed pancolitis, acute renal failure, and thrombocytopenia. The patient underwent total abdominal colectomy. Pathology confirmed ischemic colitis with scattered mesenteric microthrombi. Due to mental and respiratory decline, she remained intubated. Continuous venovenous hemodialysis was initiated. Renal failure, neurologic changes, hemolysis, thrombotic microangiopathy, and low complement levels all suggested atypical hemolytic uremic syndrome. Eculizumab 900 mg was administered intravenously on hospital day 6 and continued weekly for four doses followed by maintenance therapy. She recovered neurologically and renally after the third dose, and hematologically by the sixth dose. Her recovery has been sustained on long-term eculizumab treatment. In severe atypical hemolytic uremic syndrome, eculizumab safely reverses neurologic impairment and eliminates the need for dialysis. The optimal duration of treatment with eculizumab remains to be determined.

Keywords: eculizumab, thrombotic microangiopathy, atypical hemolytic uremic syndrome

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Readers of this article also read:

Clinical issues of mucus accumulation in COPD

Osadnik CR, McDonald CF, Holland AE

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:301-302

Published Date: 25 March 2014

Glistenings in hydrophobic acrylic intraocular lenses do affect visual function

Beiko GHH, Grzybowski A

Clinical Ophthalmology 2013, 7:2271-2274

Published Date: 27 November 2013

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:129-130

Published Date: 16 January 2013

Corrigendum

Mizoguchi T, Ozaki M, Unoki K, Dake Y, Eto T, Arai M

Clinical Ophthalmology 2012, 6:1717-1718

Published Date: 26 October 2012

Corrigendum

Chen ZQ, Liu Y, Zhao JH, Wang L, Feng NP

International Journal of Nanomedicine 2012, 7:1709-1710

Published Date: 30 March 2012

Corrigendum

Schneider EW, Johnson MW

Clinical Ophthalmology 2011, 5:1315-1316

Published Date: 16 September 2011

Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision

Espandar L, Sikder S, Moshirfar M

Clinical Ophthalmology 2011, 5:159-160

Published Date: 6 February 2011